<abstract xmlns="http://www.w3.org/1999/xhtml">
<sec><h3>Aim: </h3>
<p>Our aim was to assess the prevalence of the metabolic syndrome (MetS) and its components in patients with controlled Graves’ disease (GD).</p>
</sec>
<sec><h3>Methods: </h3>
<p>This was a cross-sectional study involving 95 consecutive patients with GD referred to our tertiary care inpatient clinical center meeting the following inclusion criteria: controlled hyperthyroidism, treatment with antithyroid drugs, untreated Graves’ orbitopathy (GO), if present. Patients’ anthropometric parameters were evaluated and laboratory tests were performed with measurement of fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, thyroid hormone and antibody levels. The presence of the MetS and its components as defined by the International Diabetes Federation from 2009 were evaluated.</p>
</sec>
<sec><h3>Results: </h3>
<p>In our patient cohort 82.1% were females, 17.9% were males, mean age 50.2 ± 13 years, with median duration of GD 16.5 months. The MetS was observed in 32.6% of our patients, obesity – in 34.7%, hyperglycemia in 38.9%, arterial hypertension – in 36.8%, low HDL-cholesterol – in 23.2% and hypertriglyceridemia – in 13.7%. There was not statistical difference neither between the prevalence of the MetS, nor between the prevalence of its individual components in female and male GD patients. The MetS was significantly more frequent in older patients, as well as abdominal obesity, hyperglycemia and arterial hypertension. There was not statistical difference in the frequency of the MetS and its components between GD patients with and without GO, except for waist circumference, which was significantly higher in patients with GO.</p>
</sec>
<sec><h3>Conclusions: </h3>
<p>The presence of the MetS and its components among GD patients are to great extent similar to those reported in the general population, which underlines the need for their screening and proper treatment in this subpopulation.</p>
</sec>
</abstract>

Aim: 
Our aim was to assess the prevalence of the metabolic syndrome (MetS) and its components in patients with controlled Graves’ disease (GD).

Methods: 
This was a cross-sectional study involving 95 consecutive patients with GD referred to our tertiary care inpatient clinical center meeting the following inclusion criteria: controlled hyperthyroidism, treatment with antithyroid drugs, untreated Graves’ orbitopathy (GO), if present. Patients’ anthropometric parameters were evaluated and laboratory tests were performed with measurement of fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, thyroid hormone and antibody levels. The presence of the MetS and its components as defined by the International Diabetes Federation from 2009 were evaluated.

Results: 
In our patient cohort 82.1% were females, 17.9% were males, mean age 50.2 ± 13 years, with median duration of GD 16.5 months. The MetS was observed in 32.6% of our patients, obesity – in 34.7%, hyperglycemia in 38.9%, arterial hypertension – in 36.8%, low HDL-cholesterol – in 23.2% and hypertriglyceridemia – in 13.7%. There was not statistical difference neither between the prevalence of the MetS, nor between the prevalence of its individual components in female and male GD patients. The MetS was significantly more frequent in older patients, as well as abdominal obesity, hyperglycemia and arterial hypertension. There was not statistical difference in the frequency of the MetS and its components between GD patients with and without GO, except for waist circumference, which was significantly higher in patients with GO.

Conclusions: 
The presence of the MetS and its components among GD patients are to great extent similar to those reported in the general population, which underlines the need for their screening and proper treatment in this subpopulation.

Prevalence of Metabolic Syndrome and its Components in Patients with Controlled Graves’ Disease

Department of Endocrinology, University Hospital of Endocrinology

Acta Medica Bulgarica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Aim: 
Our aim was to assess the prevalence of the metabolic syndrome (MetS) and its components in patients with controlled Graves’ disease (GD).

Methods:...

Prevalence of Metabolic Syndrome and its Components in Patients with Controlled Graves’ Disease

Pubblicato online: 16 mar 2024

Pagine: 17 - 24

Ricevuto: 17 set 2023

Accettato: 09 nov 2023

DOI: https://doi.org/10.2478/amb-2024-0003

Parole chiave
Graves’ disease, metabolic syndrome, obesity, arterial hypertension, hyperglycemia, dyslipidemia

© 2024 M. Stoynova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Prevalence of Metabolic Syndrome and its Components in Patients with Controlled Graves’ Disease

Pubblicato online: 16 mar 2024

Pagine: 17 - 24

Ricevuto: 17 set 2023

Accettato: 09 nov 2023

DOI: https://doi.org/10.2478/amb-2024-0003

Parole chiaveGraves’ disease, metabolic syndrome, obesity, arterial hypertension, hyperglycemia, dyslipidemia

© 2024 M. Stoynova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
Graves’ disease, metabolic syndrome, obesity, arterial hypertension, hyperglycemia, dyslipidemia